AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More
ASTRAZENECA PHARMA | TORRENT PHARMA | ASTRAZENECA PHARMA/ TORRENT PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 135.0 | 37.5 | 360.1% | View Chart |
P/BV | x | 37.9 | 9.5 | 399.4% | View Chart |
Dividend Yield | % | 0.0 | 0.6 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
TORRENT PHARMA Mar-19 |
ASTRAZENECA PHARMA/ TORRENT PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 1,964 | 65.1% | |
Low | Rs | 883 | 1,245 | 70.9% | |
Sales per share (Unadj.) | Rs | 228.4 | 453.4 | 50.4% | |
Earnings per share (Unadj.) | Rs | 10.4 | 25.8 | 40.2% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 62.3 | 26.1% | |
Dividends per share (Unadj.) | Rs | 0 | 17.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 1.1 | 0.0% | |
Book value per share (Unadj.) | Rs | 98.8 | 279.2 | 35.4% | |
Shares outstanding (eoy) | m | 25.00 | 169.22 | 14.8% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 3.5 | 133.7% | |
Avg P/E ratio | x | 104.2 | 62.2 | 167.5% | |
P/CF ratio (eoy) | x | 66.4 | 25.8 | 257.9% | |
Price / Book Value ratio | x | 10.9 | 5.7 | 190.3% | |
Dividend payout | % | 0 | 65.9 | 0.0% | |
Avg Mkt Cap | Rs m | 27,008 | 271,513 | 9.9% | |
No. of employees | `000 | 1.4 | 13.6 | 10.0% | |
Total wages/salary | Rs m | 1,535 | 14,038 | 10.9% | |
Avg. sales/employee | Rs Th | 4,210.9 | 5,642.6 | 74.6% | |
Avg. wages/employee | Rs Th | 1,132.2 | 1,032.4 | 109.7% | |
Avg. net profit/employee | Rs Th | 191.1 | 320.9 | 59.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 76,728 | 7.4% | |
Other income | Rs m | 123 | 571 | 21.5% | |
Total revenues | Rs m | 5,833 | 77,299 | 7.5% | |
Gross profit | Rs m | 463 | 19,831 | 2.3% | |
Depreciation | Rs m | 147 | 6,177 | 2.4% | |
Interest | Rs m | 0 | 5,038 | 0.0% | |
Profit before tax | Rs m | 438 | 9,187 | 4.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -3,570 | 0.0% | |
Tax | Rs m | 179 | 1,254 | 14.3% | |
Profit after tax | Rs m | 259 | 4,363 | 5.9% | |
Gross profit margin | % | 8.1 | 25.8 | 31.4% | |
Effective tax rate | % | 40.8 | 13.6 | 299.3% | |
Net profit margin | % | 4.5 | 5.7 | 79.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 50,375 | 6.4% | |
Current liabilities | Rs m | 2,070 | 51,653 | 4.0% | |
Net working cap to sales | % | 20.0 | -1.7 | -1,198.5% | |
Current ratio | x | 1.6 | 1.0 | 159.0% | |
Inventory Days | Days | 72 | 92 | 78.6% | |
Debtors Days | Days | 35 | 68 | 51.1% | |
Net fixed assets | Rs m | 790 | 83,648 | 0.9% | |
Share capital | Rs m | 50 | 846 | 5.9% | |
"Free" reserves | Rs m | 2,419 | 46,397 | 5.2% | |
Net worth | Rs m | 2,469 | 47,244 | 5.2% | |
Long term debt | Rs m | 0 | 39,129 | 0.0% | |
Total assets | Rs m | 4,605 | 141,209 | 3.3% | |
Interest coverage | x | NM | 2.8 | - | |
Debt to equity ratio | x | 0 | 0.8 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.5 | 228.2% | |
Return on assets | % | 5.6 | 6.7 | 84.5% | |
Return on equity | % | 10.5 | 9.2 | 113.6% | |
Return on capital | % | 17.7 | 12.3 | 143.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 300 | 22,103 | 1.4% | |
Fx outflow | Rs m | 2,015 | 5,522 | 36.5% | |
Net fx | Rs m | -1,715 | 16,581 | -10.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 17,981 | 0.5% | |
From Investments | Rs m | -94 | -2,413 | 3.9% | |
From Financial Activity | Rs m | NA | -13,145 | 0.0% | |
Net Cashflow | Rs m | -6 | 2,380 | -0.2% |
Indian Promoters | % | 0.0 | 71.5 | - | |
Foreign collaborators | % | 75.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.3 | 7.0 | 4.3% | |
FIIs | % | 15.7 | 12.6 | 124.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 8.8 | 103.4% | |
Shareholders | 12,856 | 26,511 | 48.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: PANACEA BIOTECH BIOCON J.B.CHEMICALS NATCO PHARMA AJANTA PHARMA
Compare ASTRAZENECA PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.
METROPOLIS HEALTHCARE share price is trading up by 6% and its current market price is Rs 2,158. The BSE HEALTHCARE is down by 0.7%. The top gainers in the BSE HEALTHCARE Index are METROPOLIS HEALTHCARE (up 5.8%) and ASTRAZENECA PHARMA (up 6.8%). The top losers are ERIS LIFESCIENCES and BLISS GVS PHARMA .
ADVANCED ENZYME TECHNOLOGIES share price is trading up by 5% and its current market price is Rs 325. The BSE HEALTHCARE is down by 0.7%. The top gainers in the BSE HEALTHCARE Index are ADVANCED ENZYME TECHNOLOGIES (up 5.1%) and ASTRAZENECA PHARMA (up 6.7%). The top losers are APOLLO HOSPITALS and ERIS LIFESCIENCES .
ASTRAZENECA PHARMA share price is trading up by 6% and its current market price is Rs 3,840. The BSE HEALTHCARE is down by 0.6%. The top gainers in the BSE HEALTHCARE Index is ASTRAZENECA PHARMA (up 6.1%). The top losers are ABBOTT INDIA (down 0.1%) and SYNGENE INTERNATIONAL (down 0.1%).
For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More